Literature DB >> 8692553

Optimal control of acute cisplatin-induced emesis.

J Verweij1, R de Wit, P H de Mulder.   

Abstract

A survey by Coates and co-workers in 1983 revealed that patients ranked nausea and vomiting as the most distressing side effects of chemotherapy. In the last decade the use of high-dose metoclopramide and, especially, the introduction of the 5-HT3 receptor antagonists, have been major leaps forward in the control of chemotherapy-induced emesis. Nevertheless, since patients still consider nausea and vomiting to be the most distressing side effect of their chemotherapy there is clearly a need for further improvements. Acute emesis, which is the topic of this review, can now be controlled in the majority of patients during their first course of chemotherapy. Future focus should be on better control of emesis during subsequent courses of chemotherapy as well as on better control of delayed emesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8692553     DOI: 10.1159/000227642

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

1.  The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.

Authors:  Yigang Wang; Fang Huang; Haibo Cai; Yumei Wu; Guoqing He; Wen-Song Tan
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-07       Impact factor: 4.553

2.  Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.

Authors:  Chiao-En Wu; Chuang-Chi Liaw
Journal:  Support Care Cancer       Date:  2011-12-21       Impact factor: 3.603

3.  Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.

Authors:  R de Wit; A C de Boer; G H vd Linden; G Stoter; A Sparreboom; J Verweij
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

4.  Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma.

Authors:  Sha-Sha He; Qin-Jie Wu; Chang Yang Gong; Shun-Tao Luo; Shuang Zhang; Meng Li; Lian Lu; Yu-Quan Wei; Li Yang
Journal:  Mol Med Rep       Date:  2014-04-04       Impact factor: 2.952

5.  Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics.

Authors:  R de Wit
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.